[go: up one dir, main page]

WO1988005304A1 - Procedes de preparation de compositions medicinales, compositions obtenues par ces procedes et utilisation de celles-ci pour preparer des medicaments contre l'hepatite virale b et le syndrome immunodeficitaire acquis - Google Patents

Procedes de preparation de compositions medicinales, compositions obtenues par ces procedes et utilisation de celles-ci pour preparer des medicaments contre l'hepatite virale b et le syndrome immunodeficitaire acquis Download PDF

Info

Publication number
WO1988005304A1
WO1988005304A1 PCT/EP1988/000034 EP8800034W WO8805304A1 WO 1988005304 A1 WO1988005304 A1 WO 1988005304A1 EP 8800034 W EP8800034 W EP 8800034W WO 8805304 A1 WO8805304 A1 WO 8805304A1
Authority
WO
WIPO (PCT)
Prior art keywords
extraction
plant
medium
boiling point
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1988/000034
Other languages
English (en)
Inventor
Felicia Ivone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
William Blanc & Cie
Original Assignee
William Blanc & Cie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William Blanc & Cie filed Critical William Blanc & Cie
Publication of WO1988005304A1 publication Critical patent/WO1988005304A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/746—Morinda
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger

Definitions

  • the present invention relates to a process of preparation of a medicinal composition called "DUANA PAKEN HEPATITIS B" as well as to processes of preparation of medicinal compositions respectively called "SAKARIA AIDS I” and “SA ARIA AIDS II”.
  • the invention further relates to the compositions obtained by these processes and to the use of the composition called "DUANA PAKEN HEPATITIS B" for the preparation of a medicine against hepatitis B virus and hepatitis virus "non A, non B” , as well as to the use of the compositions called "SAKARIA AIDS I” and “SAKARIA AIDS II” for the preparation of medicines against acquired immunodeficiency syndrome.
  • the invention results from the discovery of new therapeutic properties of medicinal compositions obtained by extracting simultaneously in boiling water or aqueous medium specified parts of several plants which grow in South East Asia, and in particular in Indonesia, and which have already been individually used in traditional medicine in that part of the world. It should be noted that therapeutic properties of the composition according to the invention are different from a simple addition of the known healing virtues of each of the plants used in this preparation.
  • Andrographis paniculata This plant has been used to combat general frailness as well as colic, dysentry, certain forms of dyspepsia and anorexia, cachexy and syphilitic ulcers. Its leaves and roots are considered to possess febrifuge, stomachic and tonic properties.
  • This plant contains the alcaloide called "cycleine" which imparts to it a very bitter taste. It has a very high starch content and contains about 10% fat. Its leaves may be used to prepare a jelly which is considered as a medicine against gastric troubles.
  • the leaves of this plant contain an essential oil and its fruits are used in traditional medicine against dysentry and asthma as well as a desobstruent and as an emmenagogue.
  • the juice, obtained by squeezing its leaves, is applied externally.
  • the roots are cathartic and it has been reported that a decoction of the roots has an emetic and laxative effect.
  • the infusions of the leaves are considered as emolients, sedatives and stomachic.
  • the tubercles have been used as a remedy against diabetes, as well as against infections of the throat and the respiratory organs and against tuberculosis of the lung.
  • Curcuma domestica (Curcuma longa) and Curcuma xanthorrhiza :
  • the process of preparation of a medicinal composition called “DUANA PAKEN HEPATITIS B” comprises the steps of simultaneously subjecting leaves, stalks and/or roots, of the plant “Andrographis paniculata", leaves of the plant “Cyclea barbata” , fruits and kernels of the plant "Morinda citrifolia” and roots of the plant “Merremia mammosa” to extraction in aqueous medium.
  • the process of preparation of a medicinal composition called “SAKARIA AIDS I” comprises the steps of simultaneously subjecting leaves, stalks and/or roots of the plant “Andrographis paniculata", leaves of the plant “Cyclea barbata", fruits and kernels of the plant "Morinda citrifolia” and roots of the plant “Merremia mammosa” to extraction in aqueous- medium so as to obtain a first aqueous extract, and then simultaneously subjecting leaves, stems and/or roots of the plant "Andrographis paniculata” and roots of the plant "Merremia mammosa” to extraction by said first aqueous extract so as to obtain a second aqueous extract which constitutes the final product.
  • the process of preparation of a medicinal composition called “SAKARIA AIDS II” comprises the steps of simultaneously subjecting leaves, stalks and/or roots of the plant “Andrographis paniculata", leaves of the plant “Cyclea barbata", fruits and kernels of the plant "Morinda citrifolia” and roots of the plant “Merremia mammosa” to extraction in aqueous medium so as to obtain a first liquid extract, and then simultaneously subjecting rhizomes of the plant "Curcuma domestica” and rhizomes of the plant "Curcuma xanthorriza” to extraction in said first liquid extract so as to obtain a second liquid extract which constitutes the final product.
  • the gathering conditions and the treatment of the parts of the plants preliminary to the preparation of the composition are preferably the following:
  • the parts used are collected from fresh plants, aged between 6 months and one and a half year. They are washed and then dried in the sun, preferably on glass plates until they are completely dessicated, taking care not to let them turn brownish yellow or black in colour. After drying, the leaves, branches and roots are cut up into pieces of 5 to 8 cm.
  • Leaves of plants aged between one year • and a half and two years are collected and washed several times in cold water, taking care not to crush them. After this, each leaf is cut up into three parts. Only fresh leaves are used.
  • Fresh fruit which is ripe or almost ripe is gathered from plants between four and six years old. The fruits are washed in warm water until they are clean, then each fruit is cut up into eight to ten pieces and the kernel is taken out.
  • Tubercules from plants aged two to three years and a half are picked out and washed in warm water several times until they are clean. After- that, they are peeled, taking off the skin very thinly, then cut up into slices having preferably a width of 2 to 3 mm. During the peeling of the roots, the gum initially white, turns to brown and will run out.
  • the rhizomes are taken from plants aged between one year and a half and three years and washed in warm water several times until they are clean. Thereafter, the rhizomes are peeled, taking out the skin very finely, then cut up into slices of preferably 2 to 3 mm in width. During the peeling step, a yellow gum will flow out of the rhizomes.
  • the rhizomes are taken from plants aged between one and a half year and three years and washed several times in warm water until they are clean. Thereafter, the rhizomes are peeled, taking out the skin very finely, then cut into slices of preferably 1 to 1.5 mm in width. During the peeling step, a gum will flow out of the rhizomes. Said gum which is initially yellowish subsequently turns to brown-yellow in colour.
  • a stirring device and a security valve which prevents the pressure inside the recipient from surpassing a value equal to or slightly greater than atmospheric pressure parts of the plants designated above by the letters A, B, C and D, to be extracted in water are placed in four respective layers and the total volume of the water used as an aqueous extraction medium is added.
  • the initial disposition in the cooking vessel and the relative proportions of the parts of the plants to be extracted are the following (for an initial total volume of 8 litres of water by way of aqueous extraction medium) :
  • Plant “D” 18 kg (corresponding to the weight of the fresh or partially dried roots, before peeling and cutting into slices)
  • Plant “C” 12 kg (pieces of fresh fruit)
  • Plant "B” 4 kg (parts of fresh leaves)
  • Plant “A” 6 kg (pieces of leaves, stems and dried roots)
  • the extraction is carried out by progressively increasing the temperature of the water from room temperature to boiling point in 5 hours, then maintaining the extraction medium at boiling point for 3 hours, during a second heating phase immediately subsequent to the first one. At the end of this second heating step, the volume of liquid medium is reduced to about 4 or 5 litres from the initial amount of 8 litres.
  • One finally carries out the third heating phase which consists of maintaining the extraction medium at boiling point for about one hour and- a half, while stirring up three of four times in order to mix the different parts of the contents of the cooking vessel.
  • This liquid product constitutes the medicinal composition according to the invention.
  • Plant "D” 4 to 6 kg (weight of the fresh or partially dried roots before they are peeled and cut up in slices)
  • the respective durations of the first, second and third phases of the heating process are 5 hours, 2 hours and 1 hour.
  • compositions obtained by proceeding as described above can be stored for several weeks, or even several months, preferably in a cool place and in a water-tight container, without any change except for an increase in its bitterness and astringency.
  • compositions In order to improve its keeping properties, it may be useful to reheat the composition several times, for example about every 4 days during the first few days following its preparation.
  • liquid extracts obtained in the manner indicated above can be used either as a pharmaceutical potion to be administered orally to the patient, or for the preparation of other medical forms such as tablets, pellets, capsules or injectable liquid. To this end, one can proceed in an appropriate manner according to the usual preparation techniques for galenical methods and for industrial pharmaceutical products.
  • the medicinal compositions obtained as described in the above examples 1 and 2 are efficient for the treatment of hepatitis virus "non A, non B". Moreover, they are equally seen to have a curative effect against chronic ulcers and intestinal infections of the lungs and the kidneys, and more generally a beneficial effect in view of the purification of the blood and the elimination of infectious agents, such as the viruses, within the whole organism.
  • the doses to be given depend on the illness to be treated, as well as on the constitution and general state of health of the patient.
  • the "strong" composition obtained in the manner described above-
  • the "strong" composition should only be administered to patients who are not suffering from other illnesses such as, for example, diabetes, further to viral B hepatitis.
  • the "weak" composition can be administered to patients suffering from acute hepatitis B or to those suffering, in addition to hepatitis B, from additional illnesses such as diabetes or other complications relating to their general health.
  • the dosage for the "weak" composition can be favourably 50 to 60 ml, three times a day, for a non diabetic patient.
  • the dose can be reduced to 30 to 4 ml, twice a day during the first four days, then reduced to 50 to 60 ml twice a day the following days, alternating with the administration of the usual medicine against diabetes.
  • intestinal contractions may occur 4 to 8 times, after taking the liquid extract, during the first 3 or 4 days, as well as a very pronounced diuretic and sudorific effect, which generally disappears after 3 or 4 days of continuous treatment.
  • the patent should drink large quantities of sugared water (except, of course, in the case of a diabetic patient, where the "strong" dosage is counter-indicated) .
  • Patients should preferably rest during- the duration of the treatment. They can eat normally, avoiding spices, alcohol and products with a high fat content, especially oils. A vegetarian diet is particularly appropriate. Patients should moreover refrain from smoking.
  • a treatment followed as outlined above permits an improvement in the patient's condition after only 3 to 4 days, with a complete cure in 2 to 4 weeks in cases of moderate acute chronic hepatitis, 3 to 4 weeks in the case of chronic viral hepatitis and 3 to 6 weeks in the case of hepatitis with complications.
  • the initial disposition in the vessel and the relative proportions of the parts of the plants destined to be extracted are the following (for an initial volume of 12 litres of water) :
  • Plant “D” 18 to 20 kg (corresponding to the weight of fresh or partially dried roots, before being peeled and cut up into slices)
  • Plant "A” 7 kg (bits of leaves, stalks and dried - roots)
  • Plant “B” 4 to 6 kg (parts of fresh leaves).
  • the extraction is carried out by progressively increasing the temperature of the water from room temperature to boiling point in 5 hours, then maintaining the extraction medium at boiling point . for 3 hours, during a second heating step immediately subsequent to the first one. At the end of this second heating step, the volume of the liquid medium is reduced to about 5 or 6 litres.
  • a final extraction is then carried out, bringing progressively the extraction medium to boiling point.
  • the final extraction liquid which constitutes the desired medicinal composition, is of a colour analogous to that of the first liquid extraction. It has a sharp, sweet and very bitter taste.
  • This composition can be kept for several weeks, or even several months, preferably in a cool place and in a water tight container without any change in its composition other than a progressive increase in its bitterness and astringency.
  • composition obtained in the manner indicated above such as a pharmaceutical potion to be administered orally to the patient or for the preparation of other medicinal forms such as tablets, pellets, capsules or injectable liquid.
  • a pharmaceutical potion to be administered orally to the patient or for the preparation of other medicinal forms such as tablets, pellets, capsules or injectable liquid.
  • other medicinal forms such as tablets, pellets, capsules or injectable liquid.
  • the medicinal composition obtained in the above indicated manner is highly effective in treating AIDS (Acquired Immunodeficiency Syndrome) .
  • the doses to be given depend on the constitution and general state of health of the patient.
  • the liquid composition obtained in the manner described above may be given orally in doses of 40 to 50 ml, taken at intervals of three hours.
  • the doses should preferably be reduced to 30 to 40 ml every three hours.
  • the medicinal composition obtained as described in the present Example 3 can be given either alone or alternatively with the medicinal composition called "SAKARIA AIDS II" , the preparation method of which is described above and in the following Example 4.
  • the initial disposition in the vessel and the relative proportions of the parts of the plants to be extracted are the following (for an initial total volume of 12 litres of water) :
  • Plant “D” 18 to 20 kg (corresponding in weight to fresh or partially dried roots, before being peeled and cut up in slices) .
  • Plant “A” 7 kg (pieces of leaves, stalks and dried roots)
  • Plant “B” 4 to 6 kg (parts of fresh leaves).
  • the extraction is carried out by raising the temperature of the water progressively from room temperature to boiling point in 5 hours, then maintaining the extraction medium at boiling point for 3 hours during a second heating period which is immediately subsequent to the first one. At the end of this second heating step, the volume of liquid medium is reduced to about 5 or 6 litres.
  • the rhizomes, of the two plants "E” (2 to 3 kg) and “F” (3 to 4 kg) are then placed in two distinct overlying layers and 5 to 6 litres of the first liquid extract to be used as the extracting medium for the final extraction are added into the vessel.
  • a final extraction is then carried out, bringing progressively in three hours the extraction medium to boiling point.
  • the final liquid extract which constitutes the desired medicinal composition has a colour analogous to that of the first liquid extraction. Its taste is sharp, sweet and very bitter. This composition can be kept for several weeks, or even several months, preferably in a cold place and in a water tight container, without any change occuring in its composition other than a progressive increase in its bitterness and its astringency.
  • composition obtained as describen in Example 4 can be administered orally to ' the patient, or for the preparation of other medicinal forms such as tablets, pellets, capsules or injectable liquid. To this end, one can proceed in the appropriate manner according to the usual galenic preparation techniques and for industrial pharmaceutical products.
  • the medicinal composition obtained in the above indicated manner is effective in treating AIDS (Acquired Immunodeficiency Syndrome) .
  • the doses to be given depend on the constitution and the general health of the patient.
  • the liquid composition obtained in the manner described above may be given orally in doses of 40 to 50 ml, taken at 3 hourly intervals.
  • the dose For the treatment of patients who have a very weak general condition, it is preferable to reduce the dose to 30 to 40 ml, to be taken every three hours.
  • the medicinal composition obtained according to the present Example 4 can be given either alone or alternatively with the medicinal composition called "SAKARIA AIDS I", the preparation method of which is described above in particular in Example 3.
  • the patient In order to fortify the patient's organism and to avoid dehydration and the inherent weakening as a result of the diuretic and sudorific effect, the patient should drink large quantities of sugared water.
  • the patient should preferably rest during the duration of the treatment. He can eat normally, but must avoid spices, alcohol and products with a high fat content, especially oils. A vegetarian diet is particularly appropriate. The patient should moreover refrain from " smoking.
  • a treatment regularly followed, without interruption, according to the conditions mentioned in Examples 3 and 4 above, will permit, in general, a cure after 6 to 8 weeks.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Médicaments contre l'hépatite virale B, l'hépatite virale ''non A, non B'' et le syndrome immunodéficitaire acquis, préparés par extraction simultanée dans de l'eau bouillante ou en milieu aqueux des parties ci-après des plantes suivantes: Andrographis paniculata: feuilles, branches, racines. Cyclea barbata: feuilles. Morinda citrifolia: fruits et noyaux. Merremia mammosa: tubercules. Curcuma domestica: rhizomes. Curcuma xanthorrhiza: rhizomes. Les extraits liquides ainsi obtenus peuvent être administrés oralement ou utilisés pour la préparation d'autres formes médicinales. Ces médicaments ont un effet bénéfique par le fait qu'ils purifient le sang et éliminent les agents infectieux dans tout l'organisme.
PCT/EP1988/000034 1987-01-21 1988-01-20 Procedes de preparation de compositions medicinales, compositions obtenues par ces procedes et utilisation de celles-ci pour preparer des medicaments contre l'hepatite virale b et le syndrome immunodeficitaire acquis Ceased WO1988005304A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CH20787 1987-01-21
CH20687 1987-01-21
CH205/87-6 1987-01-21
CH207/87-0 1987-01-21
CH20587 1987-01-21
CH206/87-8 1987-01-21

Publications (1)

Publication Number Publication Date
WO1988005304A1 true WO1988005304A1 (fr) 1988-07-28

Family

ID=27171900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1988/000034 Ceased WO1988005304A1 (fr) 1987-01-21 1988-01-20 Procedes de preparation de compositions medicinales, compositions obtenues par ces procedes et utilisation de celles-ci pour preparer des medicaments contre l'hepatite virale b et le syndrome immunodeficitaire acquis

Country Status (2)

Country Link
AU (1) AU1226288A (fr)
WO (1) WO1988005304A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411733A (en) * 1992-04-27 1995-05-02 Hozumi; Toyoharu Antiviral agent containing crude drug
WO2000067711A1 (fr) * 1999-05-08 2000-11-16 Hwang, Jae-Kwan Procede de preparation de xanthorrhizol a partir de curcuma xanthorriza roxb et utilisations de ce produit
US6440468B1 (en) 1994-08-03 2002-08-27 A.S.A.C. Pharmaceutical International, A.I.E. Method for obtaining apolar and polar extracts of curcuma and applications thereof
WO2002083159A1 (fr) * 2001-04-17 2002-10-24 Morinda, Inc. Effets palliatifs du jus et de l'huile de morinda citrifolia
WO2003097000A1 (fr) * 2002-05-16 2003-11-27 Lg Household & Health Care Ltd. Composition pouvant ameliorer la sante bucco-dentaire
US7244463B2 (en) 2005-10-18 2007-07-17 Tahitian Noni International, Inc. Garcinia mangostana L. enhanced animal food product
WO2007080546A3 (fr) * 2006-01-11 2007-11-15 Procter & Gamble Compositions et procédés utiles pour le traitement d'une maladie respiratoire
US7442395B2 (en) 2002-11-14 2008-10-28 Tahitian Noni International, Inc. Formulation for treating candidiasis using Morinda citrifolia
WO2011074001A2 (fr) 2009-12-18 2011-06-23 Shiv Prakash Ratnam Composition hépatoprotectrice d'origine végétale
US8025910B2 (en) 2006-05-12 2011-09-27 Tahitian Noni International, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
US8535741B2 (en) 2006-05-12 2013-09-17 Morinda, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
US8574642B2 (en) 2000-12-05 2013-11-05 Tahitian Noni International, Inc. Antiviral Morinda citrifolia L. based formulations and methods of administration
US8652546B2 (en) 2007-09-06 2014-02-18 Tahitian Noni International, Inc. Morinda citrifolia based formulations for regulating T cell immunomodulation in neonatal stock animals
US8790727B2 (en) 2000-12-05 2014-07-29 Tahitian Noni International, Inc. Morinda citrifolia and iridoid based formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COMMONWEALTH AGRICULTURE BUREAU, CAB, Ref. No. 77764229, R.R. KALEYSA, "Screening of Indigenous Plants for Anthelmintic Action Against Human Ascaris Lumbricoides. Part II"; & INDIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, Vol. 19, No. 1, 1975, p. 47-49. *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0568001A3 (fr) * 1992-04-27 1995-07-05 Tsuneo Namba Agent antiviral contenant un médicament brut.
US5411733A (en) * 1992-04-27 1995-05-02 Hozumi; Toyoharu Antiviral agent containing crude drug
US6440468B1 (en) 1994-08-03 2002-08-27 A.S.A.C. Pharmaceutical International, A.I.E. Method for obtaining apolar and polar extracts of curcuma and applications thereof
WO2000067711A1 (fr) * 1999-05-08 2000-11-16 Hwang, Jae-Kwan Procede de preparation de xanthorrhizol a partir de curcuma xanthorriza roxb et utilisations de ce produit
US6696404B1 (en) 1999-05-08 2004-02-24 Lg Household & Healthcare Antibacterial composition having xanthorrizol
US8574642B2 (en) 2000-12-05 2013-11-05 Tahitian Noni International, Inc. Antiviral Morinda citrifolia L. based formulations and methods of administration
US8790727B2 (en) 2000-12-05 2014-07-29 Tahitian Noni International, Inc. Morinda citrifolia and iridoid based formulations
WO2002083159A1 (fr) * 2001-04-17 2002-10-24 Morinda, Inc. Effets palliatifs du jus et de l'huile de morinda citrifolia
US7018662B2 (en) * 2001-04-17 2006-03-28 Morinda, Inc. Palliative effects of morinda citrifolia oil and juice
WO2003097000A1 (fr) * 2002-05-16 2003-11-27 Lg Household & Health Care Ltd. Composition pouvant ameliorer la sante bucco-dentaire
US7442395B2 (en) 2002-11-14 2008-10-28 Tahitian Noni International, Inc. Formulation for treating candidiasis using Morinda citrifolia
US7244463B2 (en) 2005-10-18 2007-07-17 Tahitian Noni International, Inc. Garcinia mangostana L. enhanced animal food product
WO2007080546A3 (fr) * 2006-01-11 2007-11-15 Procter & Gamble Compositions et procédés utiles pour le traitement d'une maladie respiratoire
US8025910B2 (en) 2006-05-12 2011-09-27 Tahitian Noni International, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
US8535741B2 (en) 2006-05-12 2013-09-17 Morinda, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
US8652546B2 (en) 2007-09-06 2014-02-18 Tahitian Noni International, Inc. Morinda citrifolia based formulations for regulating T cell immunomodulation in neonatal stock animals
WO2011074001A2 (fr) 2009-12-18 2011-06-23 Shiv Prakash Ratnam Composition hépatoprotectrice d'origine végétale

Also Published As

Publication number Publication date
AU1226288A (en) 1988-08-10

Similar Documents

Publication Publication Date Title
KR100404979B1 (ko) 숙취해소용 음료 및 그 제조 방법
US6416795B1 (en) Herbal extract composition for stress prevention and treatment
WO1988005304A1 (fr) Procedes de preparation de compositions medicinales, compositions obtenues par ces procedes et utilisation de celles-ci pour preparer des medicaments contre l'hepatite virale b et le syndrome immunodeficitaire acquis
Singh et al. Ethnomedicinal value of traditional food plants used by the Zeliang tribe of Nagaland
CN106993698A (zh) 一种清热排毒下火的组合物、饮料及其制备方法
Reid A Handbook of Chinese Healing Herbs: An Easy-to-Use Guide to 108 Chinese Medicinal Herbs and Dozens of Prepared Herbal Formulas
CN107095995B (zh) 一种治疗胃炎和胃溃疡的药物组合物及制备方法
KR100379973B1 (ko) 숙취해소용 한약조성물 및 이의 제조방법
KR102247702B1 (ko) 위염 또는 소화성궤양 예방 또는 치료용 조성물
CN1058399C (zh) 一种降低尼古丁危害的保健茶和保健饮料
CN101360430B (zh) 用于治疗过敏的功能性食物组合物、利用该组合物的天然茶及其制备方法
CN115530276B (zh) 一种健脾植物饮及其制备方法和应用
CN106070783A (zh) 一种薏米祛湿茶的生产工艺
KR100609643B1 (ko) 피부염 치료용 생약 조성물 및 그 제조방법
KR102672400B1 (ko) 마늘껍질을 유효성분으로 포함하는 식음료의 제조방법
RU2098108C1 (ru) Апитерапевтическое средство
KR101379368B1 (ko) 창이자 추출물을 유효성분으로 포함하는 알코올 중독 치료용 조성물 및 그 제조 방법
CN108925807A (zh) 一种降糖降压的固体饮料及其制备方法
KR102215936B1 (ko) 밤을 포함하는 피로회복용 쌍화탕 건강기능식품 조성물 및 그 제조방법
KR100815333B1 (ko) 한약재를 이용한 건강식품 및 그 제조방법
KR102494072B1 (ko) 생약 추출물을 포함하는 우울감 개선 또는 예방용 조성물 및 이의 제조방법
KR102388251B1 (ko) 경옥고 성분을 포함하는 경옥생원 조성물의 제조방법
KR20160082568A (ko) 열수추출용 옻 조성물 및 그 옻 조성물을 이용한 추출액의 제조방법
JPH0533690B2 (fr)
KR20030079289A (ko) 숙취해소용 탄산음료 제조방법 및 그 조성물.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CH DE DK FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1988901041

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1988901041

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642